Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | PHASE1 | RECRUITING | 71 | — | — | Jan 8, 2025 | Jan 1, 2028 | Jan 21, 2025 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Castration-resistant prostate cancer | EXPERIMENTAL | Evofosfamide + zalifrelimab + balstilimab |
| Pancreatic cancer | EXPERIMENTAL | Evofosfamide + zalifrelimab + balstilimab |
| Human papilloma virus-negative squamous cell carcinoma of the head and neck | EXPERIMENTAL | Evofosfamide + zalifrelimab + balstilimab |
| Name | Type | Description |
|---|---|---|
| Evofosfamide | DRUG | Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3. |
| Zalifrelimab | DRUG | Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5. |
| Balstilimab | DRUG | Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1. |
Inclusion Criteria: 1. Histologically confirmed locally advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, or HPV-negative SCCHN for which no other lines of standard therapy with demonstrated clinical benefit are available or appropriate as treatment. 2. Appropriate to ...